| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $12.9M | -16.0% |
| SG&A Expense | $6.9M | -7.8% |
| Operating Income | -$19.8M | +13.3% |
| Net Income | -$19.0M | +14.6% |
| EPS (Basic) | -$1.11 | +22.4% |
| EPS (Diluted) | -$1.11 | +22.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $18.5M | -3.1% |
| Current Assets | $18.6M | -3.0% |
| Total Assets | $18.6M | -3.0% |
| Current Liabilities | $8.9M | +27.3% |
| Total Liabilities | $8.9M | +27.3% |
| Stockholders' Equity | $9.7M | -20.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$12.2M | +23.2% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $11.7M | -22.8% |